$GNPX #Bullish #Nasdaq $2.61 +4.91% Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer | NASDAQ https://www.nasdaq.com/press-release/genprex-doses-first-patient-in-acclaim-3-clinical-study-of-reqorsar-immunogene